BHC
NYSEBausch Health Companies Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Price$5.37-0.21 (-3.68%)
2026-03-052026-06-08
News · 26 weeks56+275%
2025-12-142026-06-07
Mix2790d
- Insider14(52%)
- Other6(22%)
- SEC Filings4(15%)
- Earnings2(7%)
- Leadership1(4%)
Latest news
25 items- SECSEC Form SD filed by Bausch Health Companies Inc.SD - Bausch Health Companies Inc. (0000885590) (Filer)
- PRBausch Health's Aesthetic Business, Solta Medical, Earns Prestigious Trademark Certification of Thermage® in ChinaThermage®, a pioneer in non-invasive skin tightening, was awarded the AAA Well-Known Trademark Certification, the highest recognition in China's domestic trademark evaluation system.LAVAL, QC, May 28, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, and Solta Medical, a global leader in the medical aesthetics market, are proud to announce that their flagship brand, Thermage®, was awarded the prestigious AAA Well-Known Trademark Certification ("AAA") by the China Trademark Association (CTA), a renowned accreditation reserved for top-tier brands. This elite distinction—earned by only 217 brands across mainland China—recognizes
- INSIDERDirector Wechsler Amy B was granted 45,871 shares, increasing direct ownership by 17% to 313,585 units (SEC Form 4)4 - Bausch Health Companies Inc. (0000885590) (Issuer)
- INSIDERDirector Roberts Eiry was granted 45,871 shares (SEC Form 4)4 - Bausch Health Companies Inc. (0000885590) (Issuer)
- INSIDERDirector Power Robert N was granted 45,871 shares, increasing direct ownership by 18% to 300,594 units (SEC Form 4)4 - Bausch Health Companies Inc. (0000885590) (Issuer)
- INSIDERDirector Paulson John was granted 45,871 shares, increasing direct ownership by 12% to 417,565 units (SEC Form 4)4 - Bausch Health Companies Inc. (0000885590) (Issuer)
- INSIDERDirector Leung Sandra was granted 45,871 shares, increasing direct ownership by 103% to 90,225 units (SEC Form 4)4 - Bausch Health Companies Inc. (0000885590) (Issuer)
- INSIDERDirector Lee Frank D. was granted 45,871 shares, increasing direct ownership by 93% to 95,210 units (SEC Form 4)4 - Bausch Health Companies Inc. (0000885590) (Issuer)
- INSIDERDirector Kavanagh Sarah B was granted 45,871 shares, increasing direct ownership by 19% to 282,230 units (SEC Form 4)4 - Bausch Health Companies Inc. (0000885590) (Issuer)
- INSIDERDirector Goettler Michael was granted 45,871 shares, increasing direct ownership by 152% to 76,020 units (SEC Form 4)4 - Bausch Health Companies Inc. (0000885590) (Issuer)
- INSIDERDirector Garcia Christian A was granted 45,871 shares, increasing direct ownership by 51% to 135,578 units (SEC Form 4)4 - Bausch Health Companies Inc. (0000885590) (Issuer)
- INSIDERDirector Lee Frank D. sold $132,796 worth of shares (24,456 units at $5.43) as part of a pre-agreed trading plan, decreasing direct ownership by 33% to 49,339 units (SEC Form 4) to cover withholding tax4 - Bausch Health Companies Inc. (0000885590) (Issuer)
- INSIDERSEC Form 3 filed by new insider Roberts Eiry3 - Bausch Health Companies Inc. (0000885590) (Issuer)
- SECBausch Health Companies Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Bausch Health Companies Inc. (0000885590) (Filer)
- PRBausch Health Announces 2026 Annual Meeting of Shareholder ResultsLAVAL, QC, May 19, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that shareholders elected all 10 director nominees at its 2026 Annual Meeting of Shareholders ("Annual Meeting") held on May 19, 2026, including Eiry W. Roberts, M.D., who was elected as a new director. Dr. Roberts brings extensive pharmaceutical leadership experience, including expertise in clinical development, medical strategy and business development, and previously served as Chief Medical Officer of Neurocrine Biosciences, Inc. Dr. Roberts will serve as chair of the Science and Technology Committee.Detailed results of the vote follow:NameForWithheldBroker Non-VotesThomas J. Appio196,
- PRBausch Health to Participate in RBC Capital Markets 2026 Global Healthcare ConferenceLAVAL, QC, May 13, 2026 /CNW/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that Thomas J. Appio, Chief Executive Officer, and Jean-Jacques Charhon, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the RBC Capital Markets 2026 Global Healthcare Conference in New York City on Wednesday, May 20, 2026. A live audio webcast of the event will be accessible on the Investor Relations section of Bausch Health's website.DetailsDate: Wednesday, May 20, 2026Time: 9:30 a.m. U.S. ETWebcast: http://ir.bauschhealth.com/events-and-presentationsA replay of the event will be available on the investor relations website following t
- PRBausch Health to Participate in Barclays 30th Annual Leveraged Finance ConferenceLAVAL, QC, May 12, 2026 /CNW/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that members of company management will participate in a fireside chat at the Barclays 30th Annual Leveraged Finance Conference in Austin, Texas on Tuesday, May 19, 2026. A live audio webcast of the event will be accessible on the Investor Relations section of Bausch Health's website.DetailsDate: Tuesday, May 19, 2026Time: 10:25 a.m. U.S. ETWebcast: http://ir.bauschhealth.com/events-and-presentationsA replay of the event will be available on the investor relations website following the event.About Bausch HealthBausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is a global,
- SECBausch Health Companies Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Bausch Health Companies Inc. (0000885590) (Filer)
- PRBAUSCH HEALTH ANNOUNCES FIRST QUARTER 2026 RESULTSFirst Quarter Consolidated Revenues of $2.52 billion, up 12% on a Reported basis and 7% on an Organic (non-GAAP)1 basis over the prior year periodGAAP Net Loss Attributable to Bausch Health of $1,423 million and GAAP Net Loss of $1,431 million, inclusive of a $1,426 million goodwill impairment chargeGAAP Loss per Share of ($3.82) (basic and diluted) compared to ($0.16) in the prior year periodAdjusted Earnings per Diluted Share (non-GAAP) of $0.78 compared to $0.59 in the prior year period, an increase of 32%Consolidated Adjusted EBITDA Attributable to Bausch Health (non-GAAP)1 of $837 million, up 27% on a Reported basis over the prior year periodBAUSCH HEALTH EXCLUDING BAUSCH + LOMB FIRST Q
- PRBausch Health's Dermatology Business, Ortho Dermatologics, Announces the Launch of Biafine®, an Iconic French Skincare Product, Through Convenient Online OrderingThe skin recovery emulsion for dry, sensitive, or stressed skin is now available through select online channelsLAVAL, QC, April 14, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its dermatology business, Ortho Dermatologics, today announced Biafine® Skin Recovery Emulsion is now offered through convenient online ordering in the United States. The well-known French skincare formula is available through select online channels.First developed in France in 1971, Biafine® is a lightweight emulsion formula designed to support the skin's natural barrier function while helping to maintain skin hydration and comfort. For decades, the formula has been recognized by dermatol
- SECSEC Form DEFA14A filed by Bausch Health Companies Inc.DEFA14A - Bausch Health Companies Inc. (0000885590) (Filer)
- SECSEC Form DEF 14A filed by Bausch Health Companies Inc.DEF 14A - Bausch Health Companies Inc. (0000885590) (Filer)
- INSIDERSEC Form 4 filed by Leung Sandra4 - Bausch Health Companies Inc. (0000885590) (Issuer)
- INSIDERSEC Form 4 filed by Paulson John4 - Bausch Health Companies Inc. (0000885590) (Issuer)
- INSIDERSEC Form 4 filed by Wechsler Amy B4 - Bausch Health Companies Inc. (0000885590) (Issuer)
BHC FAQ
6 questionsWhat does Bausch Health Companies Inc. do?
Bausch Health Companies Inc. develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb/International segment offers products with a focus on the vision care, surgical, and consumer and ophthalmology Rx products in the United States; and Solta products, branded and generic pharmaceutical products, OTC products...Where does BHC stock trade?
Bausch Health Companies Inc. (BHC) is listed on NYSE.What sector and industry is BHC in?
Bausch Health Companies Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about BHC?
Bausch Health Companies Inc. has had 8 recent analyst actions on file. The most recent action was from Barclays: Equal Weight with a $800.00 price target on 2025-12-09.What companies are similar to BHC?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare BHC side-by-side with any of them on Quantisnow.How can I track BHC on Quantisnow?
Quantisnow aggregates Bausch Health Companies Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow BHC to receive live email and push alerts on every new disclosure.